Hosted on MSN20h
Gilead reports positive HIV PrEP data for lenacapavir
Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention ...
modernghana.com2h
Inconvenient question: Science is gifting us new HIV prevention tools but is it expanding choices for the people?
Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
MedPage Today1d
Novel Weekly Oral HIV Drug Safe in Early Trial of Healthy Volunteers
Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...
The Pharma Letter1d
Lenacapavir efficacy shown in diverse range of patients
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Morningstar7d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
PURPOSE 2 is a pivotal Phase 3 trial evaluating twice-yearly lenacapavir, Gilead’s injectable HIV-1 capsid inhibitor for the investigational use of HIV prevention, among a broad and ...
BioSpace7d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
Daily Maverick6d
How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...